Filtered By:
Condition: Thrombosis
Countries: Canada Health
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 79 results found since Jan 2013.
Tobacco Use in the Myeloproliferative Neoplasms: Patient Behavior, Opinions, and Care
ConclusionsMPN patients with current or previous tobacco use demonstrate significantly higher symptom burden than non-smoking counterparts. In terms of patient care, less than half of patients who are current or previous smokers recall having a physician discuss their smoking habits with them. These results highlight the need for enhanced MPN patient counseling by health care providers, both regarding the risks of smoking and available methods to aid cessation.DisclosuresScherber: Orphan Pharmaceuticals: Honoraria; Incyte: Consultancy. Dueck: Phytogine: Employment; Pfizer: Honoraria; Bayer: Employment. Palmer: Novartis: Re...
Source: Blood - November 21, 2018 Category: Hematology Authors: Scherber, R. M., Geyer, H. L., Mazza, G., Langlais, B. T., Dueck, A. C., Palmer, J., Padrnos, L., Fleischman, A., Mesa, R. A. Tags: 902. Health Services Research-Malignant Diseases Source Type: research
Recurrent Stroke: The Role of Thrombophilia in a Large International Pediatric Stroke Population
CONCLUSIONS:Identifying children at increased for recurrent AIS events is important in intensifying preventative measures. Among 894 Canadian, English and German pediatric stroke patients, 17.9% experienced recurrent AIS at a median of 3.1 months after the index stroke. The presence of more than one prothrombotic risk factor is associated with AIS recurrence in childrenDisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Deveber, G., Kirkham, F. J., Shannon, K., Brandao, L. R., Strater, R., Kenet, G., Clausnizer, H., Moharir, M., Kausch, M., Askalan, R., MacGregor, D., Stoll, M., Torge, A., Dlamini, N., Ganesan, V., Prengler, M., Singh, J., Nowak Goettl, U. Tags: 331. Pathophysiology of Thrombosis: Poster III Source Type: research
Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified
Publication date: November 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 11Author(s): Jason G. Andrade, Marc W. Deyell, Graham C. Wong, Laurent MacleAbstractAtrial fibrillation (AF) is a progressive chronic disease characterized by exacerbations and periods of remission. It is estimated that up to 20% to 30% of those with AF also have coronary artery disease (CAD), and 5% to 15% will require percutaneous coronary intervention (PCI). In patients with concomitant AF and CAD, management remains challenging and requires a careful and balanced assessment of the risk of bleeding against the anticipated impact on i...
Source: Canadian Journal of Cardiology - November 6, 2018 Category: Cardiology Source Type: research
The 2017 hormone therapy position statement of The North American Menopause Society
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by...
Source: Menopause - October 25, 2018 Category: OBGYN Tags: Commemorative Papers Source Type: research
1. Abstract Title: Management of Cerebral Vein Thrombosis in a Large Canadian Tertiary Hospital
Introduction: Cerebral vein thrombosis (CVT) is an uncommon cause of stroke and is more likely to affect young adults and children. Women have a three-fold increased risk compared to men, owing to gender specific factors such as oral contraceptive use (OCP), pregnancy, and hormone replacement therapies. The presenting symptoms of CVT are non-specific and include headache, seizure, focal neurological deficits, or coma as the most severe presentation. The rarity and variable symptoms of the disease leads to delayed diagnosis and implementation of treatment.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Lana Castellucci, Philip Chiang Source Type: research
Effectiveness of Initiating Deep Vein Thrombosis Prophylaxis in Patients With Stroke: An Integrative Review
Venous thromboembolism (VTE) is a frequent and potentially fatal complication of immobility caused by cerebrovascular disease. This review examines the efficiency of deep vein thrombosis (DVT) prophylaxis methods. Patients with stroke initiated on DVT prophylaxis were compared with those who did not have any prophylaxis. Integrative review research design was used and included articles from 2010 to 2016. Search terms such as “DVT prophylaxis” and “stroke” were used to identify scientific publications. Of 173 studies identified, 12 articles were included and rated using the Canadian Medical Association and Center fo...
Source: Journal of Neuroscience Nursing - September 8, 2018 Category: Neuroscience Tags: Article Source Type: research
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research
Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease de-Mystified
Publication date: Available online 20 August 2018Source: Canadian Journal of CardiologyAuthor(s): Jason G. Andrade, Marc W. Deyell, Graham C. Wong, Laurent MacleABSTRACTAtrial fibrillation (AF) is a progressive chronic disease characterized by exacerbations and periods of remission. It is estimated that up to 20-30% of those with AF also have coronary artery disease (CAD), and 5-15% will require percutaneous coronary intervention (PCI). In patients with concomitant AF and CAD, management remains challenging and requires a careful and balanced assessment of the risk of bleeding against the anticipated impact on ischemic out...
Source: Canadian Journal of Cardiology - August 21, 2018 Category: Cardiology Source Type: research
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Publication date: 9–15 June 2018 Source:The Lancet, Volume 391, Issue 10137 Author(s): P J Devereaux, Emmanuelle Duceppe, Gordon Guyatt, Vikas Tandon, Reitze Rodseth, Bruce M Biccard, Denis Xavier, Wojciech Szczeklik, Christian S Meyhoff, Jessica Vincent, Maria Grazia Franzosi, Sadeesh K Srinathan, Jason Erb, Patrick Magloire, John Neary, Mangala Rao, Prashant V Rahate, Navneet K Chaudhry, Bongani Mayosi, Miriam de Nadal, Pilar Paniagua Iglesias, Otavio Berwanger, Juan Carlos Villar, Fernando Botto, John W Eikelboom, Daniel I Sessler, Clive Kearon, Shirley Pettit, Mukul Sharma, Stuart J Connolly, Shrikant I Bangdiwala, ...
Source: The Lancet - June 8, 2018 Category: General Medicine Source Type: research
Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada
AbstractCanadian guidelines recommend non vitamin K antagonists (NOACs) in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF), but NOACs are more expensive than VKAs. Canada has a universal healthcare system that covers the cost of NOACs for select patient groups. Ability to pay for NOACs may influence their use. We reviewed medical charts of Hamilton General Hospital outpatients under the age of 65 with a new diagnosis of AF who were referred for initiation of OAC therapy. We contacted these patients by phone and asked them to complete a questionnaire regarding their...
Source: Journal of Thrombosis and Thrombolysis - June 5, 2018 Category: Hematology Source Type: research
A Review of the Use of Direct Oral Anticoagulant Use in Orthotopic Heart Transplantation Recipients
Over 60 years ago, the vitamin K antagonist (VKA) warfarin was approved and remained the only oral anticoagulation agent until recently [1]. Currently, within North America and Europe there are four DOACs available. Dabigatran, first approved in Europe and Canada in 2008, then in the United States of America in 2010, followed by rivaroxaban, apixaban, and most recently edoxaban. The introduction of direct oral anticoagulants (DOACs) has been a major advancement and these agents are the preferred to VKAs for many indications [2 –5], including stroke prevention in nonvalvular atrial fibrillation (NVAF), acute treatment and...
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Rosaleen Boswell, Glen J. Pearson Tags: Review article Source Type: research
Multiple thromboembolic events from a left atrial appendage occlusion device
We report a clinico-pathological case where thrombus adherent to an incompletely endothelialized Watchman® device resulted in multiple thromboembolic events, contributing to a fatal outcome. This case illustrates uncertainties regarding the device’s endothelialization process. Teaser Left atrial appendage occlusion devices are an alternative to oral anticoagulation in patients with nonvalvular atrial fibrillation at risk of ischemic stroke. Post-implantation thromboprophylaxis is recommended, but the optimal regimen is unknown. We report a clinico-pathological case where thrombus adherent to an incompletely endotheliali...
Source: Canadian Journal of Cardiology - December 27, 2017 Category: Cardiology Source Type: research
Assessment and management of the Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation
Conclusion Integration of clinical, biomarker, and imaging risk factors can improve overall prediction for the presence of LAA thrombi, translating into improved patient selection for imaging. The gold standard for the diagnosis of LAA thrombi remains TEE, although ICE, CCT, and CMR are promising alternative modalities. When LAA thrombi are discovered, the treatment regimen remains variable, although DOACs may have similar efficacy to VKA. Future trials will help further elucidate DOAC use for the treatment of LAA thrombi.
Source: Canadian Journal of Cardiology - December 15, 2017 Category: Cardiology Source Type: research
Pharmacists as Care Providers for Stroke Patients: A Systematic Review.
CONCLUSIONS: Available evidence suggests that a variety of pharmacist interventions can have a positive impact on stroke patient outcomes. Pharmacists should be considered an integral member of the stroke patient care team.
PMID: 28929979 [PubMed - as supplied by publisher]
Source: The Canadian Journal of Neurological Sciences - September 20, 2017 Category: Neurology Authors: Basaraba JE, Picard M, George-Phillips K, Mysak T Tags: Can J Neurol Sci Source Type: research
